We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Product News   May 26, 2020

 
SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Credit: Unsplash

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Aigenpulse Introduces Novel Data Intelligence Platform to Expedite Drug Discovery and Development

Product News

Aigenpulse has introduced a new state-of-the-art data intelligence platform that is designed to expedite the drug discovery and development process.

READ MORE

TALLC Granted UK Patent for SmartCelle Ocular Drug Delivery Technology

Product News

TALLC has announced that the United Kingdom Intellectual Property Office (IPO) has granted the first in a series of SmartCelle smart micelle patents covering their novel nanotechnology for ocular drug delivery.

READ MORE

Byondis’ Investigational Antibody-Drug Conjugate Selected for Trial in Early-Stage Breast Cancer

Product News

Byondis has announced that Quantum Leap selected the company’s investigational antibody-drug conjugate SYD985 for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE